TWI772270B - 臨床調配物 - Google Patents

臨床調配物 Download PDF

Info

Publication number
TWI772270B
TWI772270B TW105126446A TW105126446A TWI772270B TW I772270 B TWI772270 B TW I772270B TW 105126446 A TW105126446 A TW 105126446A TW 105126446 A TW105126446 A TW 105126446A TW I772270 B TWI772270 B TW I772270B
Authority
TW
Taiwan
Prior art keywords
solution
cells
hours
cell
individual
Prior art date
Application number
TW105126446A
Other languages
English (en)
Chinese (zh)
Other versions
TW201717912A (zh
Inventor
羅傑 蓋
朱德森 萊利夫
洛瑪 Ｅ 索思維克
Original Assignee
美商安斯泰來再生醫藥協會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安斯泰來再生醫藥協會 filed Critical 美商安斯泰來再生醫藥協會
Publication of TW201717912A publication Critical patent/TW201717912A/zh
Application granted granted Critical
Publication of TWI772270B publication Critical patent/TWI772270B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Dentistry (AREA)
TW105126446A 2015-08-18 2016-08-18 臨床調配物 TWI772270B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206821P 2015-08-18 2015-08-18
US62/206,821 2015-08-18

Publications (2)

Publication Number Publication Date
TW201717912A TW201717912A (zh) 2017-06-01
TWI772270B true TWI772270B (zh) 2022-08-01

Family

ID=56843032

Family Applications (3)

Application Number Title Priority Date Filing Date
TW105126446A TWI772270B (zh) 2015-08-18 2016-08-18 臨床調配物
TW111127548A TWI833293B (zh) 2015-08-18 2016-08-18 臨床調配物
TW113102969A TW202417023A (zh) 2015-08-18 2016-08-18 臨床調配物

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW111127548A TWI833293B (zh) 2015-08-18 2016-08-18 臨床調配物
TW113102969A TW202417023A (zh) 2015-08-18 2016-08-18 臨床調配物

Country Status (15)

Country Link
US (3) US11013808B2 (enExample)
EP (1) EP3334415A1 (enExample)
JP (3) JP7043392B2 (enExample)
KR (3) KR102411018B1 (enExample)
CN (2) CN119112939A (enExample)
AU (2) AU2016308818B2 (enExample)
BR (1) BR112018003031B1 (enExample)
EA (2) EA202190722A1 (enExample)
HK (1) HK1256839A1 (enExample)
IL (3) IL299326A (enExample)
MX (2) MX2018002038A (enExample)
PH (1) PH12018500371B1 (enExample)
SG (1) SG10201913250SA (enExample)
TW (3) TWI772270B (enExample)
WO (1) WO2017031312A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
SG11201705379VA (en) 2014-12-30 2017-08-30 Cell Cure Neurosciences Ltd Rpe cell populations and methods of generating same
EP3869195B1 (en) 2015-03-23 2024-03-20 Astellas Institute for Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
BR112018003031B1 (pt) 2015-08-18 2023-12-26 Astellas Institute For Regenerative Medicine Solução salina de vida útil prolongada, preparação celular, seus usos, método de obtenção e armazenamento de preparação celular, composição farmacêutica e kit
KR102431887B1 (ko) * 2016-06-30 2022-08-11 가부시키가이샤 헤리오스 이식용 매체
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3086815A1 (en) * 2017-12-29 2019-07-04 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
EP4022042A1 (en) 2019-08-28 2022-07-06 Astellas Institute for Regenerative Medicine Methods of treating vascular diseases
US20220288131A1 (en) 2019-08-28 2022-09-15 Astellas Institute For Regenerative Medicine Compositions and methods of treating vascular diseases
BR112022006644A2 (pt) 2019-10-30 2022-07-12 Astellas Inst For Regenerative Medicine Métodos para a produção de células epiteliais de pigmento da retina
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
CN117915772A (zh) * 2021-07-15 2024-04-19 二氧化硅医疗产品公司 用于核酸和生物样品的防腐剂组合物及其使用方法
CA3254454A1 (en) * 2022-03-16 2025-03-04 Racthera Co., Ltd. METHOD OF TRANSPLANTATION
CA3259999A1 (en) 2022-07-18 2024-01-25 Astellas Institute For Regenerative Medicine METHODS OF TREATING A BRAIN INJURY
JP2025530638A (ja) 2022-08-23 2025-09-17 アステラス インスティテュート フォー リジェネレイティブ メディシン 光受容体レスキュー細胞（ｐｒｃ）組成物および眼障害の処置のための方法
WO2024172043A1 (ja) * 2023-02-14 2024-08-22 住友ファーマ株式会社 網膜色素上皮裂孔の治療薬
WO2025122978A1 (en) * 2023-12-06 2025-06-12 Bluerock Therapeutics Lp Cell cryopreservation and delivery vehicle and methods of using the same
FR3158635A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible particulière comprenant des éléments cellulaires hétérogènes utile pour l’administration de thérapies cellulaires
FR3158633A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible comprenant des éléments cellulaires hétérogènes
WO2025158059A1 (fr) * 2024-01-26 2025-07-31 Treefrog Therapeutics Composition biocompatible particuliere comprenant des elements cellulaires heterogenes utile pour l'administration de therapies cellulaires
WO2025204688A1 (ja) * 2024-03-26 2025-10-02 株式会社ダイセル リン脂質膜保護用液体組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0781547A1 (en) * 1995-12-22 1997-07-02 Chemedica S.A. Sodium hyaluronate based ophthalmic formulation for use in eye surgery
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
CN1102851C (zh) * 1993-06-04 2003-03-12 生物时间公司 类血浆溶液
CN103783031A (zh) * 2012-10-29 2014-05-14 四川新生命干细胞科技股份有限公司 一种细胞保存液

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562188B1 (en) * 1992-03-27 1998-09-30 Chung-Ho Chen Composition for tissues to sustain viability and biological functions in surgery and storage
US6399110B1 (en) 1997-08-22 2002-06-04 Shimizu Pharmaceutical Co., Ltd. Glucose-containing preparation
GB2336109A (en) 1998-04-07 1999-10-13 Univ Bristol Ophthalmic Irrigating Solution
CN1196489C (zh) * 2000-01-11 2005-04-13 欧得士株式会社 眼科手术用灌流液制剂
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP4248751A3 (en) 2004-01-23 2023-11-01 President and Fellows of Harvard College Improved modalities for the treatment of degenerative diseases of the retina
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
US9029146B2 (en) 2005-09-02 2015-05-12 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
KR20170102040A (ko) 2006-04-14 2017-09-06 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
CN101878295A (zh) 2007-10-12 2010-11-03 先进细胞技术公司 制备rpe细胞和rpe细胞的组合物的改良方法
CN104328087A (zh) 2008-05-06 2015-02-04 先进细胞技术公司 用于制备衍生自多能干细胞的去核类红细胞的方法
EP3441462A1 (en) 2008-05-06 2019-02-13 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
AU2010325811A1 (en) 2009-12-04 2012-06-21 Stem Cell & Regenerative Medicine International, Inc. Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
CA3080368A1 (en) 2009-12-04 2011-06-09 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
EP2596119B8 (en) 2010-07-23 2021-06-02 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
CN113786417A (zh) 2011-11-14 2021-12-14 安斯泰来再生医药协会 人rpe细胞的药物制剂及其用途
CA2857545A1 (en) 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CA2858173C (en) 2011-12-06 2023-09-26 Advanced Cell Technology, Inc. Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
AU2013201546B2 (en) 2012-12-18 2014-10-23 Gambro Lundia Ab Dialysis composition
WO2014100779A1 (en) 2012-12-21 2014-06-26 Advanced Cell Technology, Inc. Methods ofr production of platelets from pluripotent stem cells and compositions thereof
CA3177943A1 (en) 2013-03-15 2014-09-18 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
EP3189135B1 (en) 2014-09-05 2021-06-02 Astellas Institute for Regenerative Medicine Retinal ganglion cells and progenitors thereof
EP3869195B1 (en) 2015-03-23 2024-03-20 Astellas Institute for Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
BR112018003031B1 (pt) 2015-08-18 2023-12-26 Astellas Institute For Regenerative Medicine Solução salina de vida útil prolongada, preparação celular, seus usos, método de obtenção e armazenamento de preparação celular, composição farmacêutica e kit
US20220288131A1 (en) 2019-08-28 2022-09-15 Astellas Institute For Regenerative Medicine Compositions and methods of treating vascular diseases
EP4022042A1 (en) 2019-08-28 2022-07-06 Astellas Institute for Regenerative Medicine Methods of treating vascular diseases
BR112022006644A2 (pt) 2019-10-30 2022-07-12 Astellas Inst For Regenerative Medicine Métodos para a produção de células epiteliais de pigmento da retina
US20240368541A1 (en) 2021-05-03 2024-11-07 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
CN1102851C (zh) * 1993-06-04 2003-03-12 生物时间公司 类血浆溶液
EP0781547A1 (en) * 1995-12-22 1997-07-02 Chemedica S.A. Sodium hyaluronate based ophthalmic formulation for use in eye surgery
CN103783031A (zh) * 2012-10-29 2014-05-14 四川新生命干细胞科技股份有限公司 一种细胞保存液

Also Published As

Publication number Publication date
US12419958B2 (en) 2025-09-23
HK1256839A1 (zh) 2019-10-04
KR102651291B1 (ko) 2024-03-26
KR20180048722A (ko) 2018-05-10
IL291163A (en) 2022-05-01
KR20220090583A (ko) 2022-06-29
JP7449915B2 (ja) 2024-03-14
KR102411018B1 (ko) 2022-06-20
TWI833293B (zh) 2024-02-21
US20190358330A9 (en) 2019-11-28
AU2022206757A1 (en) 2022-08-18
US11957754B2 (en) 2024-04-16
IL291163B2 (en) 2023-05-01
BR112018003031A2 (pt) 2018-09-18
IL291163B1 (en) 2023-01-01
AU2016308818A1 (en) 2018-04-05
EA037915B1 (ru) 2021-06-07
US20210275673A1 (en) 2021-09-09
US11013808B2 (en) 2021-05-25
WO2017031312A1 (en) 2017-02-23
IL257551B (en) 2022-04-01
BR112018003031B1 (pt) 2023-12-26
MX2022010363A (es) 2022-09-21
CN119112939A (zh) 2024-12-13
JP2018523682A (ja) 2018-08-23
EA201890516A1 (ru) 2018-09-28
US20240350639A1 (en) 2024-10-24
US20190030168A1 (en) 2019-01-31
MX2018002038A (es) 2018-07-06
AU2016308818B2 (en) 2022-04-21
JP2024074803A (ja) 2024-05-31
PH12018500371A1 (en) 2018-08-29
EP3334415A1 (en) 2018-06-20
TW202417023A (zh) 2024-05-01
PH12018500371B1 (en) 2023-01-20
TW201717912A (zh) 2017-06-01
CN108697641A (zh) 2018-10-23
KR20230058544A (ko) 2023-05-03
JP7043392B2 (ja) 2022-03-29
TW202245816A (zh) 2022-12-01
AU2022206757B2 (en) 2024-09-05
JP2022040140A (ja) 2022-03-10
EA202190722A1 (ru) 2021-10-29
NZ740608A (en) 2023-09-29
IL299326A (en) 2023-02-01
SG10201913250SA (en) 2020-03-30
CA2995977A1 (en) 2017-02-23
IL257551A (en) 2018-04-30

Similar Documents

Publication Publication Date Title
US12419958B2 (en) Clinical formulations
KR20120102709A (ko) 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
CN108578789A (zh) 眼科粘弹剂
TW202416830A (zh) 細胞冷凍保存調配物及使用方法
CA2995977C (en) Clinical formulations
EA047097B1 (ru) Клинические композиции
NZ740608B2 (en) Clinical formulations
US20210220515A1 (en) Viscoelastic agent material
LIAO et al. Level and clinical significance of vitreous microparticles in proliferative diabetic retinopathy